Microdosing psychedelic drugs—that is, taking sub-behavioral doses of lysergic acid diethylamide (LSD) or psilocybin—is a growing practice in Western societies. Taken mainly for creative or mood-enhancing purposes, thousands of users are increasingly being exposed to (micro)doses of psychedelic drugs. In this systematic review, we searched the available evidence from human studies, focusing our results in terms of three main axes: efficacy, safety, and the influence of the placebo effect in microdosing practices. While the available evidence has some strengths (e.g. large sample sizes, robust methodologies) there are also remarkable limitations (e.g. gender bias, heterogeneity of dosing schedules and drugs used). Highly contradictory results have been found, showing both the benefits and detriments of microdosing in terms of mood, creative processes, and energy, among other regards. This review provides a general overview of the methods and approaches used, which could be useful for improving future studies.

在西方社会，微剂量迷幻药（即服用亚行为剂量的麦角酰二乙胺（LSD）或psilocybin）是一种越来越普遍的做法。主要是出于创造力或提高心情的目的，成千上万的用户越来越多地接触（微型）迷幻药物。在本系统综述中，我们搜索了来自人体研究的可用证据，并将结果集中在三个主要方面：功效，安全性以及安慰剂作用在微剂量实践中的影响。尽管现有证据具有一定的优势（例如，大样本量，稳健的方法），但也存在显着的局限性（例如，性别偏见，给药方案和所用药物的异质性）。已发现高度矛盾的结果，表明微剂量对情绪的好处和不利之处，创作过程，精力以及其他方面。这篇综述对所使用的方法和方法进行了总体概述，这可能有助于改进未来的研究。